Conoidin A|cas:18080-67-6|西域试剂

Conoidin A,98.03%

产品编号：Bellancom-116090| CAS NO：18080-67-6| 分子式：C₁₀H₈Br₂N₂O₂| 分子量：347.99

Conoidin A 是刚地弓形虫过氧化物酶 II (TgPrxII) 的细胞通透性抑制剂，有杀线虫的特性。Conoidin A 共价结合 TgPrxII 的过氧化物催化位点 Cys47，不可逆地抑制其过氧化物活性，IC50 为 23 µM。Conoidin A 也抑制哺乳动物 PrxI 和 PrxII (但不抑制 PrxIII) 的氧化。Conoidin A 具有抗氧化、神经保护作用，并且可用于缺血性心脏病的研究。

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-116090		￥500.00	杭州北京（现货）
Bellancom-116090		￥1000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Conoidin A

产品介绍

Conoidin A 是刚地弓形虫过氧化物酶 II (TgPrxII) 的细胞通透性抑制剂，有杀线虫的特性。Conoidin A 共价结合 TgPrxII 的过氧化物催化位点 Cys47，不可逆地抑制其过氧化物活性，IC₅₀ 为 23 µM。Conoidin A 也抑制哺乳动物 PrxI 和 PrxII (但不抑制 PrxIII) 的氧化。Conoidin A 具有抗氧化、神经保护作用，并且可用于缺血性心脏病的研究。

生物活性

Conoidin A is a cell permeable inhibitor of T. gondii enzyme peroxiredoxin II (TgPrxII) with nematicidal properties. Conoidin A covalently binds to the peroxidatic Cys47 of TgPrxII, irreversibly inhibiting its hyperperoxidation activity with an IC₅₀ of 23 µM. Conoidin A also inhibits hyperoxidation of mammalian PrxI and PrxII (but not PrxIII). Conoidin A has antioxidant, neuroprotective effects and can be used for the research of ischaemic heart disease.

体外研究

Peroxiredoxins are a widely conserved family of enzymes that function in antioxidant defense and signal transduction. And the changes in PrxII expression are associated with a variety of human diseases, including cancer.
Conoidin A binds to the peroxidatic cysteine of TgPrxII, inhibiting its enzymatic activity in vitro. Conoidin A also shown to alkylate or crosslink catalytic cysteines of wild type AcePrx-1 in Ancylostoma ceylanicum and human PrxII and PrxIV with similar efficiency. But it is ineffective to mitochondrial hPrxIII.
Conoidin A (5 µM) can inhibit the glucose oxidase-mediated hyperoxidation of mammalian peroxiredoxin I and II.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Conoidin A (intraperitoneal injection; 5 mg/kg; for three successive days before MI/R injury) blocks the effect of Luteolin (HY-N0162) on the ST‐segment elevation. Furthermore, an increase in the infarct size presented of the MI/R group can be reduced by Luteolin. But pre‐treatment with conoidin A abolishs the effect of Luteolin. Pre‐treatment with conoidin A also prevents Luteolin-reduced activities of CK‐MB, AST and LDH in vivo.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Rat myocardial I/R model
Dosage:	5 mg/kg
Administration:	Intraperitoneal injection; 5 mg/kg; for three successive days before MI/R injury
Result:	Significantly reversed the antioxidative effect of Luteolin. Impaired the protective effects of luteolin.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Rat myocardial I/R model
Dosage:	5 mg/kg
Administration:	Intraperitoneal injection; 5 mg/kg; for three successive days before MI/R injury
Result:	Significantly reversed the antioxidative effect of Luteolin. Impaired the protective effects of luteolin.

性状

Solid

溶解性数据

In Vitro:

DMSO : 14.29 mg/mL (41.06 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.8736 mL	14.3682 mL	28.7365 mL
5 mM	0.5747 mL	2.8736 mL	5.7473 mL
10 mM	0.2874 mL	1.4368 mL	2.8736 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 1.43 mg/mL (4.11 mM); Clear solution

此方案可获得 ≥ 1.43 mg/mL (4.11 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 14.3 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液